A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.

A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.

A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.

A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.